Radiopharm Theranostics Ltd (RADX) Stock Analysis

AI analysis of Radiopharm Theranostics Ltd (RADX)

Buy

Radiopharm Theranostics Limited (RADX) appears to be a good buy right now due to its recent positive clinical trial results and a significant price target from analysts. The stock is currently priced at $1.04, which is substantially lower than its 52-week high of $16.25, indicating potential for recovery. Additionally, the RSI is at 48.55, suggesting the stock is neither overbought nor oversold, which is favorable for entry. The recent announcement of a pivotal Phase 3 trial for RAD101, which has shown a 93% concordance in detecting brain metastases, adds to the positive outlook. However, the main risk is its current negative P/E ratio of -0.25, indicating that the company is not yet profitable, which could affect long-term performance.

Valuation Metrics

The current forward P/E ratio for Radiopharm Theranostics Ltd (RADX) is 0.00, compared to its 5-year average forward P/E of -1.05.

Forward P/E

Fair

5Y Average P/E

-1.05

Current P/E

0.00

Overvalued

0.07

Undervalued

-2.18

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-0.19

Current EV/EBITDA

-0.10

Overvalued

1.00

Undervalued

-1.37

Forward P/S

Fair

5Y Average P/S

52.46

Current P/S

0.59

Overvalued

116.38

Undervalued

-11.46

Alphio AI Price Scenarios for RADX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%RADX

$4.44

Scenario price

B

Base

Base · 50%RADX

$4.42

Scenario price

B

Bear

Bear · 25%RADX

$4.18

Scenario price

RADX FAQ — answered by Alphio AI

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation. It operates in the Healthcare sector.

Radiopharm Theranostics Limited (RADX) appears to be a good buy right now due to its recent positive clinical trial results and a significant price target from analysts. The stock is currently priced at $1.04, which is substantially lower than its 52-week high of $16.25, indicating potential for recovery. Additionally, the RSI is at 48.55, suggesting the stock is neither overbought nor oversold, which is favorable for entry. The recent announcement of a pivotal Phase 3 trial for RAD101, which has shown a 93% concordance in detecting brain metastases, adds to the positive outlook. However, the main risk is its current negative P/E ratio of -0.25, indicating that the company is not yet profitable, which could affect long-term performance.